VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
EVOEvotec SE
$2.56$909M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

EVO logoEvotec SE(EVO)Earnings, Financials & Key Ratios

EVO•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryContract development and manufacturing services
AboutEvotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Show more
  • Revenue$757M-5.0%
  • EBITDA-$40M+2.8%
  • Net Income-$99M+49.3%
  • EPS (Diluted)-0.28+50.0%
  • Gross Margin8.27%-42.6%
  • EBITDA Margin-5.25%-2.3%
  • Operating Margin-17.87%
  • Net Margin-13.13%+46.6%
  • ROE-11.26%+40.5%

EVO Key Insights

Evotec SE (EVO) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Trading at only 1.0x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 19 (bottom 19%)
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when EVO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

EVO Price & Volume

Evotec SE (EVO) stock price & volume — 10-year historical chart

Loading chart...

EVO Growth Metrics

Evotec SE (EVO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years19.48%
5 Years8.62%
3 Years0.26%
TTM-5.45%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM5.3%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM5.31%

Return on Capital

10 Years3.25%
5 Years-3.34%
3 Years-6.71%
Last Year-9.09%

EVO Recent Earnings

Evotec SE (EVO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.48-217.9%
$0.15
Rev
$217M+5.0%
$206M
Q2 2026
Apr 8, 2026
Metric
Actual
Est
EPS
$0.05-74.0%
$0.21
Rev
$348M+5.7%
$329M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.14-1.4%
$0.14
Rev
$192M-20.0%
$240M
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$0.14+19.9%
$0.18
Rev
$202M+5.1%
$192M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.48vs $0.15-217.9%
$217Mvs $206M+5.0%
Q2 2026Apr 8, 2026
$0.05vs $0.21-74.0%
$348Mvs $329M+5.7%
Q4 2025Nov 5, 2025
$0.14vs $0.14-1.4%
$192Mvs $240M-20.0%
Q3 2025Aug 13, 2025
$0.14vs $0.18+19.9%
$202Mvs $192M+5.1%
Based on last 12 quarters of dataView full earnings history →

EVO Peer Comparison

Evotec SE (EVO) competitors in Contract development and manufacturing services — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
IQV logoIQVIQVIA Holdings Inc.Direct Competitor28.47B167.7721.405.87%8.33%22.11%2.44
CRL logoCRLCharles River Laboratories International, Inc.Direct Competitor8.91B185.00-63.57-0.85%-4.59%-5.66%0.95
MEDP logoMEDPMedpace Holdings, Inc.Direct Competitor13.14B460.2030.1219.97%17.19%120.89%0.55
LSCC logoLSCCLattice Semiconductor CorporationProduct Competitor21.06B153.726893.272.72%3.46%2.79%0.11
RXRX logoRXRXRecursion Pharmaceuticals, Inc.Product Competitor1.44B3.23-2.2426.92%-8.44%-54.32%0.07
SDGR logoSDGRSchrödinger, Inc.Product Competitor1.18B15.76-11.1823.29%-40.6%-30.85%0.30
ABCL logoABCLAbCellera Biologics Inc.Product Competitor1.69B5.53-11.29160.56%-181.75%-14.22%0.13
TMO logoTMOThermo Fisher Scientific Inc.Supply Chain172.66B464.6126.193.91%15.18%13.23%0.76

Compare EVO vs Peers

Evotec SE (EVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IQV

Most directly comparable listed peer for EVO.

Scale Benchmark

vs TMO

Larger-name benchmark to compare EVO against a more recognizable public peer.

Peer Set

Compare Top 5

vs IQV, CRL, MEDP, LSCC

EVO Income Statement

Evotec SE (EVO) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
257.63M375.4M446.44M500.92M618.03M751.45M781.43M796.97M757.26M745.24M
Revenue Growth %
56.61%45.71%18.92%12.2%23.38%21.59%3.99%1.99%-4.98%-5.45%
Cost of Goods Sold
175.06M263.39M313.55M375.18M466.49M577.38M606.38M682.09M694.6M660.57M
COGS % of Revenue
67.95%70.16%70.23%74.9%75.48%76.84%77.6%85.59%91.73%-
Gross Profit
82.57M▲ 0%
112.02M▲ 35.7%
132.89M▲ 18.6%
125.74M▼ 5.4%
151.54M▲ 20.5%
174.06M▲ 14.9%
175.05M▲ 0.6%
114.88M▼ 34.4%
62.66M▼ 45.5%
84.67M▲ 0%
Gross Margin %
32.05%29.84%29.77%25.1%24.52%23.16%22.4%14.41%8.27%11.36%
Gross Profit Growth %
41.01%35.67%18.64%-5.38%20.52%14.86%0.57%-34.37%-45.45%-
Operating Expenses
43.89M49.22M58.38M77.19M110.55M153.22M222.56M257.4M197.97M189.23M
OpEx % of Revenue
17.04%13.11%13.08%15.41%17.89%20.39%28.48%32.3%26.14%-
Selling, General & Admin
42.38M57.01M66.43M77.2M105.44M156.19M169.61M188.2M123.65M172.36M
SG&A % of Revenue
16.45%15.19%14.88%15.41%17.06%20.79%21.71%23.61%16.33%-
Research & Development
17.61M35.62M58.43M59.61M65.7M76.64M68.53M50.86M74.33M36.91M
R&D % of Revenue
6.84%9.49%13.09%11.9%10.63%10.2%8.77%6.38%9.82%-
Other Operating Expenses
-209K257K-66.6M-59.63M-60.6M-79.62M-15.58M18.34M0-2M
Operating Income
37.49M▲ 0%
77.46M▲ 106.6%
62.59M▼ 19.2%
48.56M▼ 22.4%
41M▼ 15.6%
20.85M▼ 49.1%
-47.51M▼ 327.9%
-142.52M▼ 200.0%
-135.31M▲ 5.1%
-104.57M▲ 0%
Operating Margin %
14.55%20.63%14.02%9.69%6.63%2.77%-6.08%-17.88%-17.87%-14.03%
Operating Income Growth %
19.63%106.6%-19.2%-22.43%-15.57%-49.14%-327.85%-200%5.06%-
EBITDA
58.26M108.76M111.4M104.61M111.39M104.05M45.47M-40.9M-39.76M-41.11M
EBITDA Margin %
22.61%28.97%24.95%20.88%18.02%13.85%5.82%-5.13%-5.25%-5.52%
EBITDA Growth %
34.75%86.67%2.43%-6.09%6.48%-6.6%-56.3%-189.95%2.79%70.72%
D&A (Non-Cash Add-back)
20.77M31.29M48.81M56.06M70.4M83.2M92.98M101.62M95.55M73.11M
EBIT
26.83M74.59M37.96M34.3M246.23M-140.81M-68.85M-182.28M-135.31M-112.68M
Net Interest Income
-358K-1.69M-5.22M-7.13M-6.98M-4.81M-2.48M-9.26M-9.62M-9.61M
Interest Income
903K898K2.23M1.34M2.27M8.34M9.26M2.44M4.25M5.02M
Interest Expense
1.26M2.59M7.46M8.46M9.25M13.15M11.74M11.7M13.87M14.63M
Other Income/Expense
-11.16M-5.46M-6.03M-22.72M195.98M-174.81M-33.09M-51.45M12M-76.81M
Pretax Income
26.33M▲ 0%
72M▲ 173.4%
56.56M▼ 21.4%
25.84M▼ 54.3%
236.98M▲ 817.1%
-153.96M▼ 165.0%
-80.59M▲ 47.7%
-193.98M▼ 140.7%
-123.31M▲ 36.4%
-181.38M▲ 0%
Pretax Margin %
10.22%19.18%12.67%5.16%38.34%-20.49%-10.31%-24.34%-16.28%-24.34%
Income Tax
2.33M-12.06M19.33M19.56M21.47M21.7M3.32M2.1M-23.88M14.64M
Effective Tax Rate %
8.86%-16.75%34.18%75.7%9.06%-14.09%-4.12%-1.08%19.37%-8.07%
Net Income
24.26M▲ 0%
84.17M▲ 247.0%
38.16M▼ 54.7%
6.28M▼ 83.5%
215.51M▲ 3332.8%
-175.66M▼ 181.5%
-83.91M▲ 52.2%
-196.08M▼ 133.7%
-99.43M▲ 49.3%
-196.02M▲ 0%
Net Margin %
9.42%22.42%8.55%1.25%34.87%-23.38%-10.74%-24.6%-13.13%-26.3%
Net Income Growth %
-11.89%247%-54.67%-83.55%3332.78%-181.51%52.23%-133.67%49.29%5.3%
Net Income (Continuing)
25M84.06M37.31M6.28M215.51M-175.66M-83.91M-196.08M-99.43M-196.02M
Discontinued Operations
0000000000
Minority Interest
992K876K00000000
EPS (Diluted)
0.08▲ 0%
0.28▲ 250.0%
0.13▼ 53.6%
0.02▼ 84.6%
0.65▲ 3150.0%
-0.49▼ 175.4%
-0.23▲ 53.1%
-0.56▼ 143.5%
-0.28▲ 50.0%
-0.55▲ 0%
EPS Growth %
-20%250%-53.57%-84.62%3150%-175.38%53.06%-143.48%50%5.31%
EPS (Basic)
0.080.280.130.020.65-0.49-0.23-0.56-0.28-
Diluted Shares Outstanding
290.02M294.96M299.45M307.5M332.81M353.41M353.87M354.59M355.16M355.12M
Basic Shares Outstanding
290.02M294.96M299.45M307.5M332.81M353.35M353.87M353.29M355.16M355.12M
Dividend Payout Ratio
----------

EVO Balance Sheet

Evotec SE (EVO) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
180.25M249.77M527.05M806.13M1.1B1.07B903.16M681.96M762.62M712.02M
Cash & Short-Term Investments
101.58M149.88M359.22M589.67M858.5M707.31M604.11M396.8M476.19M445.23M
Cash Only
67.02M109.06M310.97M517.05M699.33M400.7M510.91M306.39M418.34M388.32M
Short-Term Investments
34.56M40.82M48.25M72.62M159.17M306.61M93.2M90.41M57.85M56.91M
Accounts Receivable
69.98M60.94M139.34M167.48M176.75M275.77M221.9M218.38M213.42M167.23M
Days Sales Outstanding
99.1459.25113.92122.03104.39133.95103.65100.02102.8794.43
Inventory
9.02M5.66M12.07M16.62M25.79M29.82M30.89M31.12M29.3M33.02M
Days Inventory Outstanding
18.87.8414.0516.1720.1818.8518.5916.6515.418.52
Other Current Assets
17.03M25.27M6.13M21.04M20.68M43.82M27.87M13.42M24.75M66.55M
Total Non-Current Assets
487.02M522.11M852.81M1.03B1.13B1.18B1.35B1.23B1.02B929.5M
Property, Plant & Equipment
74.66M90.52M268.53M412.7M484.6M650.2M806.56M823.94M554.39M531.39M
Fixed Asset Turnover
3.45x4.15x1.66x1.21x1.28x1.16x0.97x0.97x1.37x1.16x
Goodwill
220.18M220.79M287.27M302.67M257.57M274.82M275.63M282.85M272.25M0
Intangible Assets
135.03M122.99M131.33M119.95M30.85M23.82M15.45M26.44M31.56M0
Long-Term Investments
22.14M28.99M46.31M72.22M287.01M150.33M142.09M42.15M52.61M218.02M
Other Non-Current Assets
15.77M15.5M26.56M45.73M56.84M74.08M95.23M37.82M36.84M37.33M
Total Assets
667.27M▲ 0%
771.88M▲ 15.7%
1.38B▲ 78.8%
1.84B▲ 33.2%
2.24B▲ 21.6%
2.26B▲ 1.0%
2.25B▼ 0.2%
1.91B▼ 15.1%
1.78B▼ 7.0%
1.64B▲ 0%
Asset Turnover
0.39x0.49x0.32x0.27x0.28x0.33x0.35x0.42x0.43x0.41x
Asset Growth %
89.91%15.68%78.76%33.18%21.63%0.99%-0.21%-15.09%-7.03%-50.03%
Total Current Liabilities
245.78M196.28M200.88M255.06M324.52M337.71M464.57M344.58M367.92M423.82M
Accounts Payable
26.08M31.14M35.16M52.06M72.6M97.28M134.32M85.79M64.74M54.96M
Days Payables Outstanding
54.3743.1540.9250.6556.861.4980.8545.9134.0232.77
Short-Term Debt
167.76M55.07M23.27M36.72M36.14M1.56M149.1M50.8M103.64M88.71M
Deferred Revenue (Current)
18.99M61.19M82.4M86.44M126.78M136.67M107.86M109.81M108.02M383.38M
Other Current Liabilities
29.44M16.74M17.17M31.68M63.93M76.54M45.83M84.21M41.18M155.82M
Current Ratio
0.73x1.27x2.62x3.16x3.39x3.18x1.94x1.98x2.07x1.68x
Quick Ratio
0.70x1.24x2.56x3.10x3.31x3.09x1.88x1.89x1.99x1.60x
Cash Conversion Cycle
63.5723.9587.0487.5667.7791.3141.3970.7684.2580.18
Total Non-Current Liabilities
89.75M150.73M643.51M696.2M532.96M732.36M667.99M615.39M596.72M517.36M
Long-Term Debt
20.3M54.68M364.68M405.02M326.34M328.3M477.11M392.74M194.82M299.16M
Capital Lease Obligations
1.17M2.87M131.87M160.21M135.96M162M170.03M0149.04M149.04M
Deferred Tax Liabilities
23.5M21.52M78.08M73.39M17.69M18.52M18.14M14.52M79.51M121.92M
Other Non-Current Liabilities
16.11M20.62M25.3M25.62M18.49M17.4M-152.57M20.9M19.74M65.58M
Total Liabilities
335.52M347M844.39M951.26M857.48M1.07B1.13B959.98M964.64M941.17M
Total Debt
189.93M114.47M519.83M601.94M512.92M506.67M815.35M443.54M447.5M387.87M
Net Debt
122.91M5.41M208.86M84.9M-186.41M105.98M304.44M137.15M29.16M-450.47K
Debt / Equity
0.57x0.27x0.97x0.68x0.37x0.43x0.73x0.47x0.55x0.55x
Debt / EBITDA
3.26x1.05x4.67x5.75x4.60x4.87x17.93x---9.44x
Net Debt / EBITDA
2.11x0.05x1.87x0.81x-1.67x1.02x6.70x--0.01x
Interest Coverage
21.27x28.79x5.09x4.05x26.61x-10.71x-5.87x-15.58x-9.75x-7.70x
Total Equity
331.75M▲ 0%
424.88M▲ 28.1%
535.47M▲ 26.0%
886.41M▲ 65.5%
1.38B▲ 55.4%
1.19B▼ 13.8%
1.12B▼ 5.7%
952.52M▼ 14.9%
813.36M▼ 14.6%
700.35M▲ 0%
Equity Growth %
55.07%28.07%26.03%65.54%55.42%-13.83%-5.67%-14.95%-14.61%-77.92%
Book Value per Share
1.141.441.792.884.143.363.162.692.291.97
Total Shareholders' Equity
330.75M424M535.47M886.41M1.38B1.19B1.12B952.52M813.36M700.35M
Common Stock
147.53M149.06M169.39M200.56M176.61M176.95M177.19M177.55M177.7M178.06M
Retained Earnings
-566.73M-481.01M-495.22M-529.36M-216.42M-392.38M-476.29M-672.37M-775.56M-898.76M
Treasury Stock
00000000-1.55M-1.14M
Accumulated OCI
-28.9M-27.2M-21.96M-45.91M-12.64M-37.4M-30.64M-7.35M-45.09M-38.36M
Minority Interest
992K876K00000000

EVO Cash Flow Statement

Evotec SE (EVO) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
10.83M156.24M42.22M44.72M122.24M205.81M36.44M18.22M-9.06M17.85M
Operating CF Margin %
4.2%41.62%9.46%8.93%19.78%27.39%4.66%2.29%-1.2%-
Operating CF Growth %
-83.93%1342.93%-72.98%5.93%173.33%68.37%-82.29%-50%-149.75%-36.22%
Net Income
24M84.06M37.31M6.25M215.51M-175.66M-83.91M-196.08M-99.43M-196.02M
Depreciation & Amortization
20.77M31.29M48.8M56.06M67.61M83.2M92.98M101.62M95.55M49.53M
Stock-Based Compensation
2.92M4.25M3.65M5.29M7.8M9.92M9.63M5.04M00
Deferred Taxes
-6.14M-26.12M6.74M7.49M5.07M21.7M3.32M2.1M14.11M0
Other Non-Cash Items
4.97M-9.17M14.61M6.51M-171.47M161.37M24.37M173.75M39.11M119.85M
Working Capital Changes
-35.68M71.93M-68.9M-36.87M-2.28M105.28M-9.94M-68.21M-58.4M44.49M
Change in Receivables
-7.88M-1.85M-49.33M-4.18M-48.03M-53.68M00-27.6M0
Change in Inventory
814K-283K-1.36M-3.63M-11.65M-4.41M00-9.18M0
Change in Payables
1.9M5.01M-2.03M2.17M31.34M24.55M00-7.02M0
Cash from Investing
-269.03M-39.13M-86.63M-155.09M-243.85M-412.8M-13.29M-71.19M159.86M169.6M
Capital Expenditures
-17.59M-27.87M-31.32M-99.07M-118.94M-181.35M-213.32M-117.47M-79.36M-65.93M
CapEx % of Revenue
6.83%7.42%7.02%19.78%19.25%24.13%27.3%14.74%10.48%8.85%
Acquisitions
-270.32M5.17M-52.15M-33.63M-21.09M-83.82M-20.16M42.78M213.76M210.64M
Investments
----------
Other Investing
691K-2.14M-583K-6.24M-7.38M3.03M8.22M-2.78M023.33M
Cash from Financing
240.72M-77.76M211.26M246.41M398.43M-58.15M71.96M-161.42M-30.93M-89.88M
Debt Issued (Net)
148.37M-79.34M209.36M-5.16M14.77M-53.11M84.6M-152.07M-6.96M-34.24M
Equity Issued (Net)
90.25M00249.97M404.32M355K00-1.27M-1.38M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
2.11M1.58M1.9M1.59M-20.66M-5.39M-12.63M-9.35M-22.71M-54.26M
Net Change in Cash
-16.92M▲ 0%
42.04M▲ 348.4%
167.98M▲ 299.6%
145.55M▼ 13.4%
276.75M▲ 90.1%
-284.17M▼ 202.7%
95.75M▲ 133.7%
-204.52M▼ 313.6%
148.32M▲ 172.5%
99.46M▲ 0%
Free Cash Flow
-6.76M▲ 0%
128.37M▲ 1999.3%
10.31M▼ 92.0%
-54.35M▼ 627.1%
3.29M▲ 106.1%
24.46M▲ 642.5%
-179.56M▼ 834.2%
-114.02M▲ 36.5%
-78.74M▲ 30.9%
-44.92M▲ 0%
FCF Margin %
-2.62%34.2%2.31%-10.85%0.53%3.25%-22.98%-14.31%-10.4%-6.03%
FCF Growth %
-111.81%1999.29%-91.97%-627.12%106.06%642.47%-834.18%36.5%30.94%49.55%
FCF per Share
-0.020.440.03-0.180.010.07-0.51-0.32-0.22-0.13
FCF Conversion (FCF/Net Income)
0.45x1.86x1.11x7.12x0.57x-1.17x-0.43x-0.09x0.09x0.23x
Interest Paid
000000000943K
Taxes Paid
0000000000

EVO Key Ratios

Evotec SE (EVO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
8.89%22.25%7.95%0.88%19.04%-13.7%-7.27%-18.92%-11.26%-23.71%
Return on Invested Capital (ROIC)
9.17%13.13%7.99%4.25%2.84%1.26%-2.62%-8.5%-10.5%-8.1%
Gross Margin
32.05%29.84%29.77%25.1%24.52%23.16%22.4%14.41%8.27%11.36%
Net Margin
9.42%22.42%8.55%1.25%34.87%-23.38%-10.74%-24.6%-13.13%-26.3%
Debt / Equity
0.57x0.27x0.97x0.68x0.37x0.43x0.73x0.47x0.55x0.55x
Interest Coverage
21.27x28.79x5.09x4.05x26.61x-10.71x-5.87x-15.58x-9.75x-7.70x
FCF Conversion
0.45x1.86x1.11x7.12x0.57x-1.17x-0.43x-0.09x0.09x0.23x
Revenue Growth
56.61%45.71%18.92%12.2%23.38%21.59%3.99%1.99%-4.98%-5.45%
Related:EVO Dividend History·EVO Revenue History·EVO Price History·EVO P/E History·EVO Financial Ratios·EVO Institutional Holders

EVO Frequently Asked Questions

Evotec SE (EVO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Evotec SE (EVO) reported $745.2M in revenue for fiscal year 2025. This represents a 20757% increase from $3.6M in 2003.

Evotec SE (EVO) saw revenue decline by 5.0% over the past year.

Evotec SE (EVO) reported a net loss of $196.0M for fiscal year 2025.

Dividend & Returns

Evotec SE (EVO) has a return on equity (ROE) of -11.3%. Negative ROE indicates the company is unprofitable.

Evotec SE (EVO) had negative free cash flow of $44.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in EVO back in 2003?

Total return calculator · dividends reinvested · 23+ years of data

See returns →

How much would $100/month in EVO be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →